As such, ESMO and the European Thyroid Association (ETA) clinical practice guidelines for thyroid cancer recommend that all patients with clinically apparent sporadic MTC are offered genetic counselling and screening for germline RET mutations. This evidence concerns the gene RET and thyroid gland carcinoma.